ViaAqua receives $8.25m funding to enhance aquaculture disease resistance

ViAqua Therapeutics, a biotechnology firm focused on improving animal health in aquaculture, has raised $8.25m in funding led by S2G Ventures, with participation from Rabo Ventures and others. The company has developed an oral delivery platform for RNA-based solutions to enhance disease resistance in aquaculture, with an initial focus on shrimp. Shrimp farming faces significant challenges from diseases, and ViAqua's technology aims to provide an affordable and effective solution. The funding will support the production and launch of ViAqua's feed supplement for shrimp, initially targeting White Spot Virus.